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Abstract
Human amniotic membrane-derived mesenchymal stromal cells (hAMSCs) are easily
obtained in large quantities and free from ethical concerns. Promising therapeutic
results for both hAMSCs and their secreted factors (secretome) were described by
several in vitro and preclinical studies, often for treatment of orthopedic disorders
such as osteoarthritis (OA) and tendinopathy. For clinical translation of the hAMSC
secretome as cell-free therapy, a detailed characterization of hAMSC-secreted factors
is mandatory. Herein, we tested the presence of 200 secreted factors and
754 miRNAs in extracellular vesicles (EVs). Thirty-seven cytokines/chemokines were
identified at varying abundance, some of which involved in both chemotaxis and
homeostasis of inflammatory cells and in positive remodeling of extracellular matrix,
often damaged in tendinopathy and OA. We also found 336 EV-miRNAs, 51 of which
accounted for more than 95% of the genetic message. A focused analysis based on
miRNAs related to OA and tendinopathy showed that most abundant EV-miRNAs are
teno- and chondro-protective, able to induce M2 macrophage polarization, inhibit
inflammatory T cells, and promote Treg. Functional analysis on IL-1β treated ten-
ocytes and chondrocytes resulted in downregulation of inflammation-associated
genes. Overall, presence of key regulatory molecules and miRNAs explain the promis-
ing therapeutic results of hAMSCs and their secretome for treatment of musculoskel-
etal conditions and are a groundwork for similar studies in other pathologies.
Furthermore, identified molecules will pave the way for future studies aimed at more
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sharply predicting disease-targeted clinical efficacy, as well as setting up potency and
release assays to fingerprint clinical-grade batches of whole secretome or purified
components.
K E YWORD S
amnion, extracellular vesicles, inflammation, mesenchymal stem/stromal cells, osteoarthritis,
tendinopathy
1 | INTRODUCTION
Mesenchymal stromal cells (MSCs) gained privileged attention in the
field of regenerative medicine due to their combined anti-
inflammatory and tissue progenitor activating features.1 At present
(October 2020), over 1100 registered clinical trials investigating the
use of MSCs are registered (https://clinicaltrials.gov/), among which
most are related to musculoskeletal and immunological conditions.2
The most common MSCs sources are currently bone marrow and
adipose tissue,3 although ethical and safety concerns led to the search
for alternatives. Conversely, the amniotic membrane is an advanta-
geous MSC source, since placenta is normally discarded after birth
and its collection and use free from ethical controversy.
Human amniotic membrane-derived MSCs (hAMSCs) possess
strong immunomodulatory properties promoting tissue repair and
regeneration through paracrine mechanisms.4 hAMSCs suppress the
in vitro proliferation, inflammatory cytokine production, and functions
of T lymphocytes, monocytes, dendritic cells, macrophages, and natu-
ral killer cells.4-6 In addition, hAMSCs induce M2 macrophages with
anti-inflammatory, pro-regenerative characteristics and support the
expansion of regulatory T cells.4,7,8 Furthermore, both hAMSCs and
the amniotic membrane have shown promising outcomes in orthope-
dic applications. In an in vitro osteoarthritis (OA) model, hAMSCs
improved chondrocyte viability and enhanced the anti-inflammatory
M2-phenotype switch,9 while in vivo hAMSCs stimulated the repair
of cartilage defects and inhibited T-cell response.10 In humans,
hAMSCs-enriched amniotic suspension allografts (ASAs) improved
pain and functional scales of patients with symptomatic knee OA.11
Similar results were obtained in tendinopathies treatment, where ASA
and amniotic membrane fragments improved fiber alignment and
restored a physiological-like cell density in rats.12,13 Due to the above
reasons, hAMSCs are being explored in both immune-related
(NCT02172924, NCT01769755) and orthopedic (NCT03337243,
NCT03028428) clinical trials.
Nevertheless, hAMSCs functional and molecular characterization
remains fragmentary, delaying their wider translation in clinical prac-
tice. It has been proposed that MSCs mode of action is mediated by
secreted cytokines and growth factors,14 as well as different types of
extracellular vesicles (EVs),15 altogether defined as the secretome.
Consistently, hAMSC-secreted factors have been shown to induce
antiproliferative effects on T cells, skew their polarization to favor
T regulatory cells (Treg), inhibit the differentiation of monocyte-
derived dendritic cells,16,17 and decrease pro-inflammatory M1
differentiation and activation thus promoting M2 macrophage polari-
zation7,8 and activation.18 The hAMSC secretome was also able to induce
collagen production and biomechanical properties at the site of Achilles
tendon transection in rats.19 Similarly, in patients with tendinosis, injection
of amnion/chorion membrane allograft containing hAMSCs-secreted fac-
tors led to pain reduction and functional improvement,20 consistent with
what was also observed in a rabbit model with osteochondral defects.21
Furthermore, in equine models, purified hAMSC-derived EVs were dem-
onstrated to act as key players in tendon lesion healing and to exert an
anti-inflammatory effects on tenocytes, and these effects were largely
mediated by EV-embedded miRNAs.22,23 Taken together, these results
strongly support the therapeutic actions of hAMSC-released factors.
A wide screening of soluble molecules, either free or EV-con-
veyed, is therefore crucial and mandatory to predict a disease-
targeted clinical potency. Also, identification of reliable markers may
define future release assays to frame the fingerprint of clinical-grade
batches of hAMSCs secretome or purified components, such as EVs,
in order to use naïve or engineered cell-free clinical products with
increased potency. In this work, 200 soluble factors and 754 miRNAs
were quantified in the hAMSC secretome and in purified EVs, respec-
tively. Findings of the study have been critically discussed in the frame
of OA and tendinopathy to give ground to the encouraging observa-
tions reported by both in vitro and preclinical studies since, although
sharing few etiopathogenetic factors, both conditions are often
treated with similar approaches, including the use of cell therapy
products.
Significance statement
The therapeutic potential of human amniotic membrane-
derived mesenchymal stromal cells (hAMSCs) has been
addressed to both soluble factors and extracellular vesicles
(EVs). This study characterized the abundance of 200 factors
and 754 EV-miRNAs released by hAMSCs. Identified mole-
cules share protective signals in those contexts where
inflammation and degeneration have to be counteracted,
such as osteoarthritic joints or pathological tendons, and
support preliminary in vitro and preclinical studies. These
data allow for prediction of a broader disease-targeted clini-
cal efficacy, as well as the setup of potency and release
assays to fingerprint clinical-grade batches of hAMSCs cell-
free products.
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2 | MATERIALS AND METHODS
2.1 | hAMSCs isolation, expansion, and secretome
production
Human term placentas (n = 3) were collected from healthy women
and processed. hAMSCs were isolated as previously described,24 and
cultured in complete CHANG C Medium at 37C, 5% CO2, and 95%
humidity until passage 2 and 3, before secretome production and flow
cytometry analysis. Complete CHANG C medium was obtained by
adding lyophilized supplements to basal CHANG B medium (Irvine Sci-
entific, Irvine, California; see http://www.irvinesci.com/uploads/
technical-documentations/40200_Chang_C_T101_C100_Rev12.pdf),
to obtain a final concentration of 6% newborn calf serum and 6% fetal
bovine serum (http://www.irvinesci.com/chang-media-faq). For
secretome production, hAMSCs at 90% confluency were washed
three times with Phosphate Buffered Saline (PBS) to remove protein
supplements contamination, and 12 mL of serum-free and
supplement-free CHANG B medium was added per T175 cell culture
flask. Secretome was collected after 48 hours and serially centrifuged
(376g, 1000g, 2000g, and twice at 4000g, 15 minutes each) at 4C to
eliminate debris, floating cells and apoptotic bodies. Cleared secret-
ome was directly used for enzyme-linked immunosorbent assay
(ELISA) analysis or further processed for EVs isolation.
2.2 | hAMSCs characterization
Flow cytometry was performed with CytoFlex (Beckman Coulter, Ful-
lerton, California) flow cytometer (minimum 30 000 events), with
CD90-FITC (REA897), CD73-PE (REA804), CD34-FITC (AC136),
CD45-PEVIO770 (REA747) and CD31-PERCPVIO700 (REA730)
(Miltenyi, Bergisch Gladbach, Germany), and CD44-PERCP (44PP2)
(Immunostep, Salamanca, Spain) antibodies.25
2.3 | ELISA assays
The concentration of 200 soluble cytokines, receptors, chemokines,
growth, and inflammatory factors (Table S1) was determined by Qua-
ntibody Human Cytokine Array 4000, according to manufacturers'
instructions (RayBiotech, Norcross, Georgia). Only factors with positive
detection above single assays threshold in all samples were selected.
The amount per cell (ng/106 cells) was obtained by multiplying the con-
centration in ng/mL per total volume and dividing per million cells.
2.4 | Secretome protein-protein interaction
networks
Interactome maps were constructed by STRING (http://www.string-
db.org) (database v11 data accessed: July 2020). Network properties
were selected as follows: organism, Homo sapiens; meaning of net-
work edges, evidence; active interaction sources, experiments and
databases; minimum required interaction scores, medium confi-
dence (0.400).
2.5 | Identification of enriched gene ontology
terms
GOrilla tool (http://cbl-gorilla.cs.technion.ac.il/) was used sifting two
unranked lists, either ELISA or STRING 1/2 clusters and the 200 mole-
cules of the ELISA array, as targets and the background, respec-
tively.26 P value threshold <10−3.
2.6 | EVs isolation and characterization
EVs were obtained by centrifuging cleared secretome (100 000g,
9 hours, 4C) in a 70Ti rotor (Beckman Coulter). One hundred microli-
ters of PBS per initial 10 mL was used to suspend EV pellets and
processed as follows:
• Flow cytometry: After a 1:150 dilution in PBS, carboxyfluorescein
succinimidyl ester (CFSE) was added at a final concentration of
100 nM and left to incubate for 30 minutes at 37C. The following
antibodies (all from Biolegend, San Diego, California) were individ-
ually added to labeled EVs following manufacturers' instructions:
CD9-APC (HI9A), CD63-APC (H5C6), and CD81-APC (5A6) for
EV27 or CD44-APC (BJ18), CD73-APC (AD2), and CD90-APC
(5E10) as MSC markers.28 After a subsequent 1:7 dilution in PBS,
samples were analyzed with a CytoFlex flow cytometer (minimum
30 000 events) and compared with 160-200-240-500 nm fluores-
cein isothiocyanate (FITC)-fluorescent beads (Biocytex, Marseille,
France). PBS supplemented with CFSE and unstained EVs were
used as background controls.
• Transmission electron microscopy: 5 μL EVs were absorbed on
Formvar carbon-coated grids. Negative stain was performed with
2% uranyl acetate (10 minutes). Excess was removed by filter paper
before drying the grid at room temperature (RT). Samples were
examined with a TALOS L120C transmission electron microscope
(Thermo Fisher Scientific, Waltham, Massachusetts) at 120 kV.
• Nanoparticle tracking analysis (NTA): EVs were diluted 1:500 in
PBS and visualized by Nanosight LM10-HS system (NanoSight Ltd.,
Amesbury, UK). Five recordings (60 seconds) were performed. NTA
software provided high-resolution particle size distribution profiles
and concentration measurements. The same procedure was
followed for the analysis of the cleared secretome diluted 1:5 in
PBS. Dilution factors were used to calculate particle concentration.
2.7 | Amplification of EV-embedded miRNAs by
quantitative real time-polymerase chain reaction
(qRT-PCR)
Trizol reagent was used to dissolve EV pellets. RNA was extracted
with miRNeasy and RNeasy CleanUp Kits following manufacturer's
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instructions (Qiagen, Hilden, Germany). Six picograms of a non-human
synthetic miRNA (Arabidopsis thaliana ath-miR-159a) were added as a
spike-in before RNA extraction in order to monitor technical variabil-
ity during isolation and during subsequent reactions for the eventual
equalization of panels A and B of the OpenArray platform (Life Tech-
nologies). Standard reverse transcription and preamplification proce-
dures with A and B independent kits were followed for cDNAs
synthesis. As previously described,29 real-time RT-PCR analysis with
the QuantStudio 12 K Flex OpenArray Platform (QS12KFlex) was per-
formed on A and B miRNA panels, that together cover 754 human
miRNA sequences from the Sanger miRBase v21. CRT ≥ 28 were con-
sidered as unamplified reactions. After equalization of A and B plates
for each sample by ath-miR-159a CRT values, the global mean normali-
zation was used.30 CRT values for each amplified miRNA were
reported.
2.8 | EV-miRNAs hierarchical clustering
ClustVis package (https://biit.cs.ut.ee/clustvis/) was used to generate
heat map plots for EV-miRNAs using normalized CRT values for each
sample. Clustering options were: distance for rows-correlation, method
for rows-average, and tree ordering for rows-tightest cluster first.
2.9 | EV-miRNAs target identification and
functional analysis
miRNA targets were annotated with DIANA-miRPath v.3 (http://snf-
515788.vm.okeanos.grnet.gr/), using microT-CDS to score for predicted
miRNA-mRNA interactions (threshold 0.8) in CDS or 30-UTR. For a more
stringent analysis, an heat map of significant (P < .05) miRNA signatures
in the biological process gene ontology (GO) database was generated
with the miRPath DB v2.0 heat map calculator (https://mpd.bioinf.uni-
sb.de/heatmap_calculator.html?organism=hsa) (database-Gene Ontology
Biological Processes, evidence-experimental [strong], minimum number
of significant miRNAs a pathway should have to be shown-1 or 10),
using only experimentally validated miRNA-mRNA interactions. Experi-
mentally strong miRNA-mRNA interactions shared by miR-24-3p and
miR-146a-5p were eventually submitted to PANTHER web interface
(http://www.pantherdb.org/) to identify proteins encompassing the same
functional classifications, under v15.0 database and following settings:
more than 50% of submitted proteins to display a functional category
and “GO Biological Process complete” annotated data set (GO Ontology
database released on March 23, 2020). False discovery rate calculation
and P value <.05 with Fisher's exact test type were also selected.
2.10 | Functional test
Chondrocytes were obtained from three OA (Kellgren Lawrence III or
IV) patients undergoing total hip arthroplasty by harvesting cartilage
with a scalpel from nonweight bearing superficial areas of femoral
head/neck. Chondrocytes were isolated by enzymatic digestion with
0.15 wt%/vol% type II collagenase (Worthington Biochemical, Lake-
wood, New Jersey). Tenocytes were obtained from discarded frag-
ments of the semitendinosus and gracilis tendons harvested from
three patients who underwent elective anterior cruciate ligament
reconstruction using hamstring tendons. Tenocytes were isolated by
enzymatic digestion with 0.3 wt%/vol% type I collagenase
(Worthington Biochemical). Both chondrocytes and tenocytes were
cultured in Dulbecco's modified Eagle medium (DMEM) + 10% phos-
phate buffered saline (FBS) and expanded until use. At passage 3 and
90% confluence, both cell types were cultured for 48 hours in
CHANG C medium, CHANG C medium supplemented with 1 ng/mL
IL-1β or hAMSC secretome (generated in CHANG B medium) sup-
plemented with 1 ng/mL IL-1β and related supplements to obtain the
complete “C” formulation. The medium/cells ratio was set to 5 mL per
250 000 cells in 25 cm2 flasks. After treatment, cells were collected
and frozen at −80C until RNA extraction.
RNA was extracted using RNeasy Plus Mini Kit (Qiagen, Freder-
ick, Maryland). cDNA synthesis was performed using iScript cDNA
Synthesis Kit (Biorad, Hercules, California). qRT-PCR was performed
using iTaq Universal SYBR Green Supermix (Biorad) reagent and
transcript-specific primers (COL1/2/3, MMP1/13, CXCL8, TGFB,
COX2, IL6; sequences available on request), following the manufac-
turer's instructions. For each sample, independent qRT-PCR reactions
in technical duplicate were performed using a StepOnePlus real-time
PCR system thermocycler (Applied Biosystems, Thermo Fisher Scien-
tific). TBP and ACTB were used as housekeeping genes for cho-
ndrocytes and tenocytes, respectively, to score transcript modulation
across samples with the ΔΔCt (cycle threshold) method.
2.11 | Statistical analyses
Only EV-miRNAs or factors detected in all samples were considered.
GraphPad Prism software (GraphPad, San Diego, California) was used
for statistical analysis. The level of significance for the different tests
was set to a minimum P value of <.05 or <10−3, depending on ana-
lyses and algorithms' parameters.
3 | RESULTS
3.1 | hAMSCs and EVs phenotypic characterization
CD73, CD90, and CD44 MSC cell-surface antigens were highly
expressed in hAMSCs, whereas hemato-endothelial markers CD31,
CD34, and CD45 were not expressed (Figure 1A).
EV batches had an average protein concentration of 0.08
± 0.01 μg/μL and 2.62 × 109 ± 0.33 particles/μg total protein, there-
fore depleted of major contaminants, such as protein aggregates or
lipoproteins, that may affect size distribution profiling.31 As assessed
by NTA, EVs in both secretome and after isolation shared a superim-
posable dimensional profile, confirming that ultracentrifugation does
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not affect vesicle integrity or allow selection of a subpopulation
(Figure 1B). EVs were within expected dimensional range (mode of
84.1 ± 1 nm and 89 ± 1.4 nm for conditioned medium (CM) and after
purification, respectively). In purified EVs, >75% resulted below
200 nm with a D50 of 122.4 ± 4 nm, thus enriched in small vesicles/
exosomes. Absence of particles larger than 500 nm indicated efficient
apoptotic bodies and cell debris removal. Transmission electron
microscopy (TEM) supported NTA dimensional range (Figure 1C). Fur-
thermore, CFSE staining confirmed vesicle integrity after ultracentri-
fugation and, by comparison with FITC-nanobeads
(160-200-240-500 nm), size-range data were again validated
(Figure 1D). MSC-EV defining markers such as CD44, CD73 and
CD90, and other generic EV-markers such as CD63 and CD81 were
detected (Figure 1E). CD9 resulted weakly expressed on the entire
population (Figure 1E), similar to other adult and foetal MSC-EVs.29,32
3.2 | hAMSCs secreted factors
The average protein concentration for the entire secretome was 0.32
± 0.02 mg/mL. Thirty-seven molecules were detected in all donors
(Table 1). Correlation analysis showed a strong similarity (R2 = 0.99 for
F IGURE 1 hAMSCs and hAMSC-EVs phenotype characterization. A, Flow cytometry analysis of MSC staining (positive for CD44, CD73, and
CD90; negative for hemato-endothelial markers CD31, CD34, and CD45), confirming hAMSCs identity. Representative plots are shown. B, EVs size
distribution by NanoSight particle tracking analysis in both CM (blue dots) and purified EVs (orange dots). A representative plot from the same
hAMSC donor is shown. C, Transmission electron micrographs of EVs showing particles with characteristic cup-shaped morphology. D, The
resolution of the FITC-fluorescent reference bead mix indicates the flow cytometer performance in light scattering at default settings. The cytogram
depicts the SSC-H vs 535/35 (green fluorescence triggering) channel, with four fluorescent nanobead populations (160, 200, 240, and 500 nm)
compared with CFSE-stained EVs (in green the positive events), allowing their identification and gating in the FITC channel (CFSE+ gate) vs
background noise, debris, and unstained particles. E, After CFSE+ gating, with respect to Ab-unstained samples (in gray), Ab-treated EVs showed
the presence of extracellular vesicle defining molecules CD63 and CD81, while CD9 staining gave a weak signal. EVs were also strongly positive for
MSC markers CD73 and C90. CD44 labeling allowed a complete peak shift of the population from the Ab-unstained sample, although without a
sharp separation. Representative cytograms are presented. CFSE, carboxyfluorescein succinimidyl ester; CM, conditioned medium; EVs, extracellular
vesicles; FITC, fluorescein isothiocyanate; hAMSCs, human amniotic membrane-derived mesenchymal stromal cells; MSC, mesenchymal stromal cell
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donor 1 vs 2, R2 = 0.97 for 1 vs 3, and R2 = 0.99 for 2 vs 3), thus an
average intensity value for each molecule was reported. Considering
1 million cells, only IGFBP4 was secreted with an amount higher than
100 ng (465 ± 57). Six molecules were between 100 and 10 ng
(IGFBP6, 92 ± 6; IGFBP3, 55 ± 29; TIMP2, 50 ± 9; SERPINE1, 19 ± 3;
INHBA, 16 ± 25; IL6, 15 ± 2). Sixteen factors were between 10 and
1 ng and 14 molecules resulted below 1 ng.
Regardless the expression level, a functional protein association
network analysis based on both experimental and database annotated
interactions identified two clusters. The first cluster was tighter and




GF IGFBP4 464 609 56 058 Insulin-like growth factor-binding protein 4
GF IGFBP6 92 274 6033 Insulin-like growth factor-binding protein 6
GF IGFBP3 55 434 28 505 Insulin-like growth factor-binding protein 3
INF TIMP2 50 298 8553 Metalloproteinase inhibitor 2
CYTO SERPINE1 19 296 3351 Plasminogen activator inhibitor 1 (Serpin E1)
CYTO INHBA 15 738 25 298 Inhibin beta A chain
INF IL6 14 667 1578 Interleukin-6
CHE SPP1 8847 3153 Osteopontin
INF TIMP1 7095 673 Metalloproteinase inhibitor 1
GF GDF15 5716 449 Growth/differentiation factor 15
REC PLAUR 5707 967 Urokinase plasminogen activator surface receptor
REC CD14 3389 1484 Monocyte differentiation antigen CD14
INF ICAM1 2894 1830 Intercellular adhesion molecule 1
INF TNFRSF1A 2850 1376 Tumor necrosis factor receptor superfamily member 1A
INF CCL2 2754 581 C-C motif chemokine 2
REC TNFRSF21 2408 2873 Tumor necrosis factor receptor superfamily member 21
GF VEGFA 2394 1770 Vascular endothelial growth factor A
CHE CXCL5 2180 539 C-X-C motif chemokine 5
CYTO TGFB1 2103 258 Human TGF-beta 1
INF CCL5 1975 566 C-C motif chemokine 5
CYTO ANG 1950 434 Angiogenin
CHE MIF 1840 1030 Macrophage migration inhibitory factor
CYTO DKK1 1740 1124 Dickkopf-related protein 1
CHE CXCL1 772 207 Growth-regulated alpha protein (C-X-C motif chemokine 1)
CHE XCL1 597 318 Lymphotactin (XC chemokine ligand 1)
INF IL11 502 254 Interleukin-11
CHE CXCL6 459 150 C-X-C motif chemokine 6
INF CCL4 431 116 C-C motif chemokine 4
CHE CCL7 360 478 C-C motif chemokine 7
INF CXCL8 347 34 Interleukin-8 (C-X-C motif chemokine 8)
REC ALCAM 290 387 CD166 antigen (activated leukocyte cell adhesion molecule)
INF CSF1 274 114 Macrophage colony-stimulating factor 1
GF PDGFA 222 243 Platelet-derived growth factor subunit A
REC TNFRSF10C 205 151 Tumor necrosis factor receptor superfamily member 10C
CHE CXCL16 195 51 C-X-C motif chemokine 16
REC FAS 175 51 Tumor necrosis factor receptor superfamily member 6
REC SCARB2 38 25 Lysosome membrane protein 2 (Scavenger receptor class B
member 2)
Abbreviation: hAMSCs, human amniotic membrane-derived mesenchymal stromal cells.
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characterized by a high degree of interactions (CCL4/5,
CXCL1/5/8/16, and TIMP2), and linked to CCL2/7. The second clus-
ter was defined by less interfactor connections (SERPINE1, VEGFA,
TGFB1, TIMP1, IL6, CSF1, SPP1, and IGFBP3/4), and linked to
IGFBP6, INHBA, and PLAUR (Figure 2).
GO enrichment analysis was performed using the 200 factors as
the background data set. When all 37 molecules were sifted, only two
GO (biological process [BP]) terms were identified (GO:0043687,
post-translational protein modification, P value 6.61 × 10−4;
GO:2000501, regulation of natural killer cell chemotaxis, 9.83 × 10−4)
(Table S2). After having refined the search for the most abundant pro-
teins (>10 ng), we found two BP (GO:0010648, negative regulation of
cell communication, 1.34 × 10−4, GO:0023057, negative regulation of
signalling, 1.34 × 10−4), defined by the same proteins, and three
molecular function (MF) terms (GO:0005520, insulin-like growth fac-
tor binding, 2.74 × 10−4; GO:0031994, insulin-like growth factor I
binding, 2.74 × 10−4; GO:0031995, insulin-like growth factor II
binding, 2.74 × 10−4), all defined by IGFBP3/4/6 (Table S2). Searching
for the less expressed factors (<10 ng), one BP (GO:2000501, regula-
tion of natural killer cell chemotaxis, 3.33 × 10−4) and one MF
(GO:0042802, identical protein binding, 8.98 × 10−4) terms were
found to be enriched (Table S2).
Last, GO enrichment was performed on the two clusters identi-
fied by functional association analysis. The first cluster allowed for the
identification of several BP related to immune cells chemotaxis
(GO:0030595, leukocyte chemotaxis, 2.83 × 10−5; GO:0030593, neu-
trophil chemotaxis, 9.27 × 10−5; GO:0071621, granulocyte chemo-
taxis, 1.14 × 10−4) and migration (GO:1990266, neutrophil migration,
1.14 × 10−4; GO:0097530, granulocyte migration, 1.68 × 10−4;
GO:0050900, leukocyte migration, 2.82 × 10−4), supporting a general
influence on cell movement (GO:0060326, cell chemotaxis,
9.77 × 10−5) (Table S2). Also, four MF related to receptor binding
resulted enriched (Table S2). When the components of the second
cluster were analyzed, six BP, mainly related to regulation of cell
F IGURE 2 Functional association network for identified secreted factors. Using the online tool STRING, protein-protein interaction levels for
37 proteins of the hAMSCs CM were mined. The blue connections are for proteins with known interactions based on curated databases; red
connections for proteins with experimentally determined interactions. Empty nodes, proteins of unknown 3D structure; filled nodes, known or
predicted 3D structure. hAMSCs, human amniotic membrane-derived mesenchymal stromal cells. CM, conditioned medium
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growth and metabolic processes (GO:0051248, negative regulation of
protein metabolic process, 1.81 × 10−4; GO:0040008, regulation of
growth, 2.83 × 10−4) were identified (Table S2). Eventually, one MF
was enriched (GO:0001968, fibronectin binding, 6.87 × 10−4)
(Table S2). As a whole, the combination of functional association and
GO enrichment allowed a strong fingerprinting of hAMSCs secreted
factors towards immune cell chemotaxis and growth/metabolism.
3.3 | hAMSC-EVs miRNAs
Three hundred thirty-six differently expressed miRNAs were detected
in EVs. Hierarchical clustering showed a more similar profile for
hAMSCs 1 and 3 (Figure 3), albeit correlation analysis again empha-
sized consistent homogeneity (R2 = 0.94 for donor 1 vs 2, R2 = 0.95
for 1 vs 3, and R2 = 0.96 for 2 vs 3). Thus, an average CRT value was
calculated (Table S3). The most expressed miRNA resulted to be miR-
24-3p, followed by miR-146a-5p.
To handle such a large amount of data, consistent with recent
reports, even for most abundant MSC EV-miRNAs, there are approxi-
mately 1.3 molecules per vesicle,33 and 100 EVs would be needed to
shuttle one copy to a target cell.34 Since a few thousand MSC-EVs are
incorporated per day in several cell types,35-37 it is presumable that
only miRNAs present at least at 1% of most abundant ones might be
incorporated with at least one molecule. Therefore, only the first
51 EV-miRNAs, covering 95% of the EVs genetic message, were taken
into consideration (Table S3).
Many of the selected miRNAs are predicted to regulate hundreds
to thousands of transcripts, with miR-106-5p potentially targeting up
to 1433 genes and the two most abundant miRNAs, miR-24-3p and
miR-146a-5p, 582 and 413, respectively (Table S4). GO analysis based
only on experimentally validated targets identified 144 enriched BP
(data not shown), with the vast majority shared by several miRNAs.
To obtain a more solid picture, only BP potentially regulated by at
least 10 miRNAs were selected. Twenty-three miRNAs were able to
define 124 terms, encompassing different BP such as, among others,
cell death (GO:0008219, 16 miRNAs), apoptotic process
(GO:0006915, 11), cell cycle (GO:0007049, 10), cell differentiation
(GO:0030154, 13), cell communication (GO:0007154, 13), develop-
mental process (GO:0032502, 10), immune system development
(GO:0002520, 10), gene expression (GO:0010467, 14), and signaling
(GO:0023052, 12) (Figure 4). For several of these processes, both
positive and negative related terms were found, therefore hindering
an unambiguous effect.
Regarding miR-24-3p and miR-146a-5p, accounting for one third
of the EV genetic weight, nine enriched BP were shared, including cell
death (GO:0008219), apoptotic process (GO:0006915) and five terms
related to cell cycle, like regulation of cell cycle (GO:0051726), both
positive and negative (GO:0045787/GO:0045786) and cell cycle
arrest (GO:0007050) (Figure 5). Experimentally validated transcripts
targeted by both miRNAs were analyzed and the following seven
emerged: BRCA1, CARD10, CCNA2, CCND1, FAF1, NOTCH1, and
TGFB1. GO analysis revealed 85 BP (encompassing at least four
genes, Table S5), including 20 terms defining metabolic pathways,
such as regulation of metabolic process (GO:0019222, 7 genes) of
several type of macromolecules such as protein (GO:0051246,
7 genes), nitrogen (GO:0051171, 7 genes), phosphate
(GO:0019220, 6 genes), and RNA (GO:0051252, 6 genes). Notably,
also regulation of gene expression (GO:0010468, 6 genes), cell cycle
(GO:0007049, 5 genes), apoptotic process (GO:0006915, 4 genes),
and cell death (GO:0008219, 4 genes) were defined. Nevertheless,
in general, unfocused prediction based solely on target genes, with-
out tissue or disease context, led to a heterogeneous picture unable
to fully and consistently predict a single miRNA or miRNome effect
or therapeutic potency.
3.4 | Target and effect prediction of hAMSC-EV
miRNAs in the setting of musculoskeletal conditions
Due to the considerations above, we focused our attention on miRNA
involved in two widespread musculoskeletal conditions, OA and
tendinopathies, both characterized by tissue degeneration and
inflammation.
F IGURE 3 Heat map of hierarchical clustering analysis of the
normalized CRT values of detected miRNAs in the three hAMSC-EVs
under study. Rows are centered. The sample clustering tree is shown
at the top. The color scale shown in the map illustrates the expression
levels of factors, as CRT values, across all samples: red shades = high
expression (low CRT values) and blue shades = low expression (high
CRT values). EVs, extracellular vesicles; hAMSCs, human amniotic
membrane-derived mesenchymal stromal cells
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F IGURE 4 Visualization of the target enriched GO biological processes annotation regulated by EV-miRNAs. Heat map of the target
significant and enriched GO BP annotations shared by at least 10 miRNAs among those laying in the 51 most abundant miRNAs. The color scale
shown in the map illustrates the significance, as P value, for each BP: dark blue = high significance (low P value) and light blue = low significance
(high P value). BP, biological process; EV, extracellular vesicle; GO, gene ontology
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F IGURE 5 Heat map of the target significant and enriched GO BP annotations shared by the two most abundant hAMSC-EVs miRNAs,
miR-24-3p and miR-146a-5p. P values for each GO BP term are shown. The color scale shown in the map illustrates the significance, as P value,
for each BP: dark blue = high significance (low P value) and light blue = low significance (high P value). BP, biological process; EV, extracellular
vesicle; GO, gene ontology; hAMSCs, human amniotic membrane-derived mesenchymal stromal cells
TABLE 2 miRNAs involved in cartilage processes
Function % EV-genetic weight Target Role
Protective
miR-24-3p 17.73 P16INK4A Senescence
miR-222-3p 4.87 HDAC-4 ECM
miR-125b-5p 2.68 ADAMTS-4 ECM
miR-193b-3p 2.37 TGFB2, TGFB3, MMP-19 Inflammation, ECM
miR-17-5p 1.25 p62/SQSTM1 Autophagy
miR-320-3p 1.09 BMI-1, RUNX2, MMP-13 Viability, ECM
miR-92a-3p 1.04 ADAMTS-4, ADAMTS-5, HDAC2 ECM
miR-210-3p 0.51 DR6, HIF-3α Apoptosis, ECM
miR-199a-3p 0.39 COX-2 Catabolism
miR-26a-5p 0.30 iNOS, KPNA3 Homeostasis
miR-130a-3p 0.25 TNFa Inflammation
miR-30a-3p 0.23 ADAMTS-5 ECM
miR-149-5p 0.23 TNFa Inflammation
miR-193a-5p 0.19 TGFB2, TGFB3, MMP-19 Inflammation, ECM
Total 33.12
Destructive
miR-21-5p 3.81 GDF-5 Chondrogenesis
miR-30b-5p 1.96 BECN1, ATG5 Apoptosis, ECM
miR-34a-5p 0.55 SIRT1 Apoptosis
miR-16-5p 0.30 SMAD3 ECM
miR-181a-5p 0.21 ZNF440 Inflammation
Total 6.85
Pro/Des
miR-146a-5p 16.41 TRAF6/SMAD4 Proliferation/Early OA
miR-145-5p 1.02 TNFRSF11B/SOX9, SMAD3 Proliferation/ECM
Total 17.43
Abbreviations: ECM, extracellular matrix; EVs, extracellular vesicles.
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By comparing the top 51 EV-miRNAs with miRNAs reported to
be involved in OA pathogenesis,38 14 protective and 5 destructive
miRNAs were identified (Table 2). As a whole, protective miRNAs,
including miR-24-3p, represented 33.12% of EVs genetic weight vs
the 6.85% represented by the destructive ones. Notably, two miRNAs
associated with a dual role in OA cartilage were present (17.43%),
with miR-146a-5p (16.41%) being the most abundant.
Performing the same comparison with miRNAs recently discov-
ered to be involved in tendon homeostasis and tendinopathies,39,40
six were found involved in homeostasis and healing (Table 3), includ-
ing miR-146a-5p, and as a whole they represented 23% of the EV
genetic weight. Intriguingly, in a fragmented patchwork of MFs, all six
miRNAs were outlined to be involved in inflammatory processes, and
their downregulation during tendon injuries linked with an increase of
inflammatory signaling.
A closer look at T lymphocytes and macrophages, both active
players in OA and tendinopathy,41,42 revealed 10 miRNAs that play a
relevant role in modulating proliferation, activation, and differentia-
tion towards the inflammatory T helper-1 (Th1) subset, or directly
involved in modulating the polarization of CD4+ T lymphocytes
towards the regulatory T-cell subset (Table 4). In particular, miR-146a-
5p and miR-125b-5p, that encompassed 19% of the EV weight, were
shown to be involved in the negative regulation of T lymphocyte pro-
liferation and activation. Three (18.76%) were shown to be directly
involved in the downregulation of IFNγ expression, where miR-24-3p
(17.73%) represented the main contributor. Furthermore, six miRNAs
were reported to modulate Treg homeostasis, three of which (19%;
predominantly miR-146a-5p with 16.41%) favor Treg while the other
three (2.47%) inhibit Treg.
TABLE 3 miRNAs involved in tendon processes
Function % EV-genetic weight Target Role
Protective
miR-146a-5p 16.41 IRAK1, TRAF6 Inflammation
miR-193b-3p 2.37 COL2, ACAN, SOX5, MAPK, IRF1, IRAK1, NF-κβ Inflammation, ECM
miR-100-5p 2.32 NF-κβ, MAPK, IL-6R, PTK2 Inflammation, proliferation
miR-145-5p 1.02 JAK/STAT pathway Inflammation
miR-29a-3p 0.82 IL-33 Inflammation, ECM
miR-181a-5p 0.21 IFN-γ, MAPK1, IL-5, IRAK1 Inflammation, oxidative stress
Total 23.15
Abbreviations: ECM, extracellular matrix; EVs, extracellular vesicles.















miR-146a-5p 16.41 Inhibit STAT1 stabilization/
downregulates IFNy
transcription
miR-99a-5p 2.39 Reduce mTOR expression




miR-31-3p 0.18 Inhibit iTreg polarization
miR-92a-3p 1.04 Inhibit iTreg polarization
miR-17-5p 1.25 Inhibit iTreg polarization
Total 2.47
Abbreviation: EV, extracellular vesicle; mTOR, mammalian target of rapamycin.
TABLE 5 miRNAs involved in macrophage polarization
Function % EV-genetic weight Role
M1 related
miR-125b-5p 2.67 Pro M1
miR-145-5p 1.02 Pro M1
miR-130a-3p 0.25 Pro M1, anti M2
Total 3.94
M2 related
miR-24-3p 17.73 Pro M2, anti M1
miR-146a-5p 16.41 Pro M2, anti M1
miR-222-3p 4.87 Pro M2
miR-34a-5p 0.55 Pro M2
miR-181a-5p 0.21 Pro M2, anti M1
Total 39.78
Abbreviation: EV, extracellular vesicle.
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Five miRNAs involved in M2 and three involved in M1 phenotype
regulation were identified (Table 5).43 The presence of miR-24-3p and
miR-146a-5p, responsible for the M1 to M2 switch, and miR-222-3p,
involved in the control of M2 polarization, tips the balance toward a
more pronounced influence on M2 phenotype. As a whole, the weight
of M2-related miRNAs was 40% vs 4% for M1-related miRNAs.
3.5 | Functional analysis of the effect of the
hAMSC secretome on inflamed chondrocytes and
tenocytes
Several of the secreted factors and EV-embedded miRNAs suggest
anti-inflammatory and regenerative features of the hAMSC secretome
on immune cells, chondrocytes or tenocytes. A well-consolidated
amount of data has already demonstrated the net anti-inflammatory
and phenotype-switch outcomes on immune cells (see Section 4). For
this reason, to validate bioinformatics, we focused our attention on
chondrocytes and tenocytes that were treated for 48 hours with
1 ng/mL IL-1β, and markers reported to be involved in matrix remo-
deling (COL1, COL2 for chondrocytes and COL3 for tenocytes, MMP1
and MMP13) and inflammation (CXCL8, TGFB, COX2, and IL-6) were
tested by qRT-PCR (Figure 6A). As expected, IL-1β treatment resulted
in a consistent modulation of the analyzed genes, and tenocytes had a
stronger response for both inflammatory and matrix markers when
compared to chondrocytes. When the hAMSC secretome was admin-
istered together with the inflammatory stimulus, a trend toward
inflammation reduction emerged (Figure 6B), with both cell types
behaving similarly, and confirming our bioinformatics prediction.
4 | DISCUSSION
Herein we characterized an array of 200 soluble factors and a panel
of 754 miRNAs in the hAMSC secretome and EVs, respectively. Sev-
eral of these molecules are involved in immune-related and tissue res-
toration processes, therefore in accordance with in vitro and
preclinical results observed with hAMSCs and their secretome. As per
our scientific interest, data were analyzed in view of the possibility to
treat musculoskeletal conditions such as OA and tendinopathy, paving
the way for a broader use of hAMSCs or their secretome in similar
clinical applications.
Many of the most abundant secreted factors are involved in the
remodeling and homeostasis of the extracellular matrix (ECM) that is
heavily altered in both OA and tendinopathies.44,45 We found high
levels of tissue inhibitor of metalloproteinases 1 and 2 (TIMP1 and
TIMP2) in the hAMSC secretome. TIMP levels were reported by
others to decrease in diseased tendons of rabbits,46 and the expres-
sion of TIMP1 was shown to inhibit ECM degradation by
metalloproteinase 2 (matrix metallo proteinase 2, MMP2).47 More-
over, administration of MMP inhibitors was shown to reduce collagen
degradation after rotator cuff damage in rats,48 and to favor tendon-
bone healing in chronic tendinosis in humans.49 Similarly, in damaged
cartilage, TIMPs regulate ECM remodeling by directly inhibiting
MMPs.44 Also, in a canine model, TIMP2 was described to be poorly
expressed in both OA cartilage50 and synovial fluids.51 Other abun-
dant secretome factors involved in ECM remodeling are SERPINE1
and PLAUR. SERPINE1 is a master suppressor of proteases and is
transiently upregulated after tendon injury52 to balance matrix remo-
deling and to mediate fibrotic adhesions by suppressing MMP activ-
ity.53 SERPINE1 was reported to have a similar role in ECM
homeostasis in OA, where SERPINE1 levels positively correlated with
cartilage synthesis54 and counteracted urokinase/tissue-type plasmin-
ogen activators (uPA/tPA), found to be elevated in OA cartilage.55
PLAUR also controls uPA activity and, consistent with a role in ECM
remodeling, is transiently upregulated during Achilles tendon healing
in rats.56 PLAUR was described to reduce plasminogen activation in
plasmin, which in turns activates MMPs degrading cartilage struc-
ture.57 Altogether, ECM-related factors in the hAMSC secretome
have a protective and healing role in both cartilage and tendons.
Notably, the three most abundant factors, insulin-like growth
factor-binding proteins (IGFBPs) 4/6/3, whose role is mainly due to
the ability to bind IGF1, are also linked with ECM. In fact, in both ten-
dons58 and cartilage,59 IGF1 stimulates ECM synthesis and cell prolif-
eration, and IGFBPs regulate IGF1 bioavailability and activity by
reducing IGF1R-dependent sequestration and also protecting IGF1
F IGURE 6 hAMSC secretome effect on
inflamed chondrocytes and tenocytes. A,
Chondrocytes (HCH) and tenocytes (TC) were
treated with 1 ng/mL IL-1β for 48 hours, and for
the indicated transcripts the Log2 Fold Change
(FC) vs CTRL is shown. B, hAMSC secretome
(SEC) was administered together with 1 ng/mL
IL-1β, and the IL-1β + SEC vs IL-1β Ratio is shown.
For both panels, averaged values from three
independent donors, each assayed in technical
duplicate, are presented. The color scale shown in
the heat maps illustrates the expression levels as
Log2FC for panel (A) and ratio for panel (B).
hAMSCs, human amniotic membrane-derived
mesenchymal stromal cells
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from pericellular proteases.60 Therefore, increased IGFBP levels may
prolong its positive effect. In this frame, in a collagenase tendinopathy
model in horses, local IGFBPs,61 as well as IGF1,62 increased during
repair. This paradigm may be of particular importance since increased
levels of circulating IGF1 do not entail their biological action locally at
the tendon, but rather only local IGF1 can stimulate and regulate colla-
gen synthesis in tendon tissue.63 Similarly, IGFBPs bind chondrocyte-
secreted IGF1 and induce the production of cartilage ECM ultimately
exerting a protective role in OA.64 Moreover, IGFPBs are normally
localized within the fibronectin network in cartilage ECM thus creating
reservoirs of IGF1 with important roles in cartilage homeostasis and
repair.65 Therefore, local administration of the hAMSC secretome may
provide exogenous IGFBPs to create ECM complexes containing fibro-
nectin and IGF1 in both cartilage and tendons.
Nevertheless, few molecules potentially harmful for both cartilage
and tendons, such as IL6 and TGFβ, were detected. IL6 is a pleiotropic
pro-inflammatory cytokine able to increase MMPs levels and is found
in OA synovial fluid and surrounding tissues.66 Accordingly, IL6 intra-
articular injections was described to reproduce OA-like cartilage
lesions in mice.67 Similarly, TGFβ is a key fibrotic mediator,68 whose
administration may lead to an increased fibrotic phenotype with
reduced mechanical strength. Also, TGFβ supplementation as OA
therapeutic induced inflammation, synovial hyperplasia, and osteo-
phyte formation.69 Therefore, a careful balance of protective and
damaging factors for tendons and cartilage must be considered,
although protective molecules are preponderant.
As a whole, hAMSCs secreted factors defined several GO annota-
tions connected with immune cell motility and chemotaxis, shaped by
CXCL1/5/8/16 and CCL2/4/5/7. This is in agreement with proteomic
analysis reports on adipose-derived mesenchymal stem/stromal cells
(ASCs), bone marrow-derived mesenchymal stem/stromal cells
(BMSCs), and Wharton's Jelly-derived mesenchymal stem/stromal cells
(WJMSCs) secretomes,29,70,71 suggesting a conserved capacity for
MSCs of different origin. Regarding CXC-chemokines members,
CXCL1/5/8 are classified as inflammatory, and CXCL16 as both inflam-
matory and homeostatic.72 Neutrophils are the main responsive cell
type since they express CXCR1/CXCR2 receptors.73 Interestingly, neu-
trophils are hardly found in chronic synovitis,74 whereas, in the early
inflammatory phase of tendinopathies they transiently accumulate to
remove debris and release a second wave of cytokines that transition
the healing process into proliferation and remodeling.75 The major tar-
get cells of CC-chemokine members such as CCL2/4/5/7 are mono-
cytes/macrophages and T cells,72 supporting the general monocyte/
macrophage chemo-attractive capacity of MSC-secretome.70 Eventu-
ally, the presence of CSF1, by reinforcing differentiation and survival
of monocytes/macrophages and anti-inflammatory M2 polarization,76
corroborates the hAMSC secretome-dependent decrease of M1 and
increase of M2 polarization.7,8 These results confirm the actions of the
hAMSC secretome on several immune cell populations.4
The profound influence on the immune system emerged also for
EV-miRNAs. Among the most abundant hAMSCs-EVs miRNAs, many
are closely related with T cells and macrophage function/polarization.
Both CD4/CD877 and inflammatory Th1 lymphocytes78 have been
isolated from synovial biopsies of OA patients. Similar results were
reported in almost all stages of tendinopathy.79 miR146a-5p regulates
CD4 and CD8 survival and inhibits activation,80 and similarly miR-
125b is a negative regulator of T-cell function and maintains CD4 T
lymphocytes in a naïve state.81 Other relevant highly represented EV-
miRNAs, such as miR-24-3p and miR-181a-5p, target IFNγ expression
in CD4 lymphocytes,82,83 while miR-29a-3p also affects differentia-
tion toward inflammatory Th1.84 Furthermore, Treg are also involved
in the inflammatory status in both OA and tendinopathy.85,86 Herein,
six of the identified miRNAs were found to be able to modulate Treg
polarization and stabilization. miR-146a-5p contrasts the polarization
toward inflammatory Th1,87 miR-99a-5p affects inducible Treg polari-
zation by targeting mammalian target of rapamycin (mTOR),88 and
miR-10a-5p also targets Treg by stabilizing the expression of FoxP3.89
Overall, the genetic weight of miRNAs favoring Treg polarization far
exceeded that of contrasting miRNAs, supporting what previously
observed using hAMSCs and their secretome in toto.7,16 Similarly, the
genetic weight of M2-polarizing EV-miRNAs, such as miR-24-3p, miR-
146a-5p, and miR-222-3p, resulted much larger than M1-inducing
miRNAs. In particular, miR-24-3p mediates the M1 to M2 transition,
and enhances the ability of IL-4 and IL-13 to generate a M2 pheno-
type.90 miR-24-3p is also a negative regulator of toll-like receptor
(TLR)-mediated pro-inflammatory cytokine production in M1 macro-
phages.91 miR-146a-5p has been reported to be higher in M2 polar-
ized macrophages and able to promote M2 polarization.92
Furthermore, miR-222-3p has been shown to reduce the amount of
SOCS3, a negative regulator of M2 promoter STAT3.93 This is in line
with the previously reported ability of hAMSC-EVs to favor M2 mac-
rophage polarization in an induced OA model, ultimately enhancing
pain tolerance with an almost complete restoration of cartilage.94
Therefore, EV-miRNAs are involved in a specific regulation of tis-
sue regeneration that goes beyond inflammation control. The two most
abundant miRNAs, miR-146a-5p and miR-24-3p, are involved in regu-
lating OA matrix remodeling. Mir-146a-5p is a crucial determinant in
OA associated knee joint homeostasis and pain symptoms, maintaining
the balance between inflammatory response and expression of pain
factors in cartilage and synovium.95 Early on in OA, cartilage miR-146a-
5p expression is increased by IL-1β and plays a key role in catabolic fac-
tor inhibition. Conversely, in severe OA its expression is reduced, lead-
ing to progressive degradation of the cartilage due to decreased
suppression of catabolic signals.96 In fact, MMP3 levels have been
reported to be negatively associated with miR-146a-5p expression,
while type II collagen and aggrecan were positively associated,
pinpointing a novel role of miR-146a-5p in driving cartilage degenera-
tion.97 miR-24-3p, that is downregulated in OA tissues, targets
p16INK4a which accumulates and enhances senescence and cartilage
catabolism.98 Consistently, miR-24-3p promotes the proliferation and
inhibits the apoptosis of rat chondrocytes.99 We also found miRNAs
involved in ECM protection, namely miR-222-3p, miR-125b-5p, and
miR-193b-3p.38 Together with miR-146a-5p and miR-24-3p and other
less-expressed miRNAs, they could confer hAMSCs EV-miRNAs a carti-
lage protection role. Similarly, several miRNAs are involved in protec-
tive mechanisms counteracting inflammation and ECM degeneration
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after tendon injury, where the role of miRNA is, at present, less
deciphered. Again, miR-146a-5p results a crucial player due to its anti-
inflammatory activity. In patients with shoulder tendinopathy and
glenohumeral arthritis, the downregulation of miR-146a-5p has been
shown to be associated with the severity of inflammation.40 Similar
downregulation during tendinopathy was also observed for miR-193b-
3p and miR-100-5p, the former of which is associated with both inflam-
matory signaling and ECM,40,100 whereas downregulation of the latter,
considering its role in the regulation of cell growth and proliferation,40
might delay repair and favor the persistence of tissue damage.
In previous work, we have shown that factors secreted by
hAMSCs are able to suppress the proliferation, inflammatory cytokine
production, and functions of T lymphocytes,7,16,17 monocytes,8 den-
dritic cells,5 macrophages,8 and are able to induce a phenotype and
functional switch of monocytes toward macrophages with anti-
inflammatory pro-regenerative M2-like features,7,8 and also support
the expansion of regulatory T cells.7,16 More recently, we demon-
strated that hAMSC-secreted factors suppress B-cell proliferation and
differentiation, with an increase of mature B cells and a reduction of
antibody-secreting cells.101 Similar findings were obtained also by Li
et al on natural killer cells.6 The efficacy of hAMSC and their secreted
factors was also confirmed in vivo in several animal models of dis-
eases where the inflammatory component plays a prevalent role such
as lung102-106 and liver107 fibrosis, wound healing,8,108,109 multiple
sclerosis,110 inflammatory bowel disease,110 colitis,110,111 sepsis,110
traumatic brain injury,112 Huntington's disease,18 arthritis,11,110,113
and tendinopathy.12,13 Herein, the bioinformatics analysis performed
in our study support the largely experimentally validated results
obtained both in vitro and in vivo for the immune regulation.
Regarding cartilage and tendon cells which are of particular inter-
est in this study, the literature currently lacks functional in vitro tests
directly assessing the ability of hAMSCs or their secretome to sup-
press inflammation and promote regenerative features such as restor-
ing the baseline levels of altered matrix components (eg, collagen) or
matrix modifying enzymes (eg, MMPs). Herein, in a model of inflam-
mation relying on IL-1β and largely used to treat chondrocytes114 and
tenocytes,115 we observed that hAMSC secretome was able to pro-
mote a trend toward restoration of homeostatic levels for both
inflammation and ECM remodeling markers altered by the inflamma-
tory stimulus. This is of crucial relevance since ECM alteration is
orchestrated by both dysregulation of collagen deposition and struc-
ture and increase of MMPs which degrade major ECM structural com-
ponents, such as aggrecan and collagen.116 Thus, gene expression
results obtained from the in vitro model of inflamed chondrocytes and
tenocytes support the bioinformatics prediction for the targeting of
inflammation and ECM degeneration related players.
Eventually, beyond the molecular explanation of hAMSCs secret-
ome anti-inflammatory and regenerative properties, the identified
molecules might also be a milestone for the future development of
potency and release assays to fingerprint clinical-grade batches of
whole secretome or purified components. In fact, due to the diversity
of MSC-based medicinal products at the level of cell source,
manufacturing process and indication, specific fingerprint signatures
are needed to ensure their quality and guide their use. To date, few
minimal criteria for defining MSCs and good manufacturing practice
(GMP)-MSCs have been proposed.25,117 However, no concluding rec-
ommendations regarding potency assays are provided, since every
MSC product, both cell-based or cell-free, is unique and quality con-
trol assays should be developed on a case-by-case and therapeutic
application basis. In this frame, future experiments that associate the
presence/abundance of herein identified molecules, both as single
players or as a disease-driven multifactorial panel, with the modula-
tion of related gene/pathway targets, will pave the way for the devel-
opment of initial and quick screening to either integrate or guide
decision-making on the implementation of more demanding potency
assays, such as immune cell inhibition or suppressor cell activation.118
Furthermore, for pathologies such as OA or tendinopathy where
potency assays are missing, immunoregulatory or tissue-protective
cytokines or miRNAs presented in this study might be a milestone for
the future development of disease-targeted potency assays since the
relevance and acceptability of the chosen potency readout largely
depends on the clinical indication. As an example, EV-enriched miR-
320-3p and miR-199a-3p are direct regulators of MMP13 and COX2
mRNAs, respectively, and both were downregulated after treatment
with the hAMSC secretome, although to rule out a direct relationship
between the two, further experiments will be necessary. Therefore,
after a rigorous validation of a direct miRNA/mRNA or cytokine/path-
way interaction for a few and selected players through functional
tests, as the one herein proposed or those previously published for
immune cells, disease-related ELISA and qRT-PCR assays performed
on the secretome or EVs might define a new time/cost-effective front
line of future standard set of assays that could be used as “release
criteria” per se or as first line of screening to proceed or not with
more sophisticated and time-consuming/costly techniques for
hAMSCs and/or their cell-free products for clinical use.
The presented study has some limitations. The number of assayed
secreted factors was limited as well as the number of miRNAs, with sev-
eral others potentially involved in inflammation, tendinopathy, or
OA. Especially for tendon diseases, to date, only a few factors or
miRNAs have been associated with the pathology or healing, and mainly
sifted for protective roles leaving degenerative players underestimated.
Also, the functional test used herein relied on an in vitro model with an
IL-1β concentration quite far from in vivo conditions in terms of load of
insult, thus possibly altering/hindering a finely tuned response of cells.
Furthermore, we focused on a limited panel of targets that should be
increased in number and further validated by specific miRNA-mRNA
interaction and augmentation/depletion-vs-effect assays and eventually
on the protein level. However, this work reports consistent insights to
explain and interpret the therapeutic effects of hAMSCs and their
secretome observed in both in vitro and preclinical studies.
5 | CONCLUSIONS
In this report, we shed light on hAMSCs secreted factors and EV-
embedded miRNAs to heal inflamed and diseased joints and tendons,
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supporting in vitro and preclinical results. Further studies will be nec-
essary to describe in more detail the secretome at proteomic,
lipidomic, or nucleic acid levels in order to better predict and translate
the overall potency of this cell-free clinical product in joint diseases at
first, and in the wide array of pathologies that could potentially bene-
fit from the off-the-shelf hAMSCs cell-free products.
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